We assessed SARS-CoV-2 seroprevalence in Japan during July–August 2023, with a focus on 2 key age groups, 0–15 and > 80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6–11 months of age (90.0%).
All Keywords
【저자키워드】 COVID-19, viruses, respiratory infections, zoonoses, SARS-CoV-2, children, elderly, Seroprevalence, Infant, Surveillance, Japan, vaccine-preventable diseases, Seroepidemiology, maternal immunity,
【저자키워드】 COVID-19, viruses, respiratory infections, zoonoses, SARS-CoV-2, children, elderly, Seroprevalence, Infant, Surveillance, Japan, vaccine-preventable diseases, Seroepidemiology, maternal immunity,